Aliskiren

Helmy M. Siragy,Santwana Kar,Peter Kirkpatrick

Nature Reviews Drug Discovery（2007）

引用 18|浏览6

暂无评分

摘要

Aliskiren (Tekturna; Speedel/Novartis) is the first in a new class of drugs that inhibit the protease renin, which has a key role in the regulation of blood pressure. It was approved by the US FDA for the treatment of hypertension in March 2007, and approved in Europe in August 2007 (where it will be marketed as Rasilez).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要